By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion reported today a 9 percent drop year over year in second-quarter revenues as licensing revenues retreated 62 percent.

For the three months ended June 30, total revenues were $304,000, down from $344,000 a year ago. While product revenues — comprised completely of sales of the company's OVA1 ovarian cancer test — rose more than 300 percent year over year to $191,000 from $45,000, license revenues fell to $113,000 from $299,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.